Carisma Therapeutics, Inc. (CARM)
| Market Cap | 25.11K |
| Revenue (ttm) | 52.63M |
| Net Income (ttm) | 8.04M |
| Shares Out | 41.85M |
| EPS (ttm) | 0.19 |
| PE Ratio | 0.00 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,913 |
| Average Volume | 82,873 |
| Open | 0.0006 |
| Previous Close | 0.0006 |
| Day's Range | 0.0006 - 0.0006 |
| 52-Week Range | 0.0001 - 1.2700 |
| Beta | 3.50 |
| RSI | 14.89 |
| Earnings Date | Apr 14, 2026 |
About Carisma Therapeutics
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo... [Read more]
Financial Performance
In 2024, Carisma Therapeutics's revenue was $19.63 million, an increase of 31.59% compared to the previous year's $14.92 million. Losses were -$60.48 million, -30.39% less than in 2023.
Financial StatementsNews
Carisma Announces Delisting from Nasdaq and SEC Deregistration
PHILADELPHIA , Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to pr...
Carisma Therapeutics Provides Corporate Updates
Company to explore strategic alternatives to advance liver fibrosis and oncology assets and reduce operational cash burn PHILADELPHIA , March 31, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq...
Carisma Therapeutics Transcript: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
The company is advancing engineered myeloid cell therapies, with a focus on mesothelin-targeted CT-1119 for solid tumors and TIM4-based CT-2401 for liver fibrosis. Key milestones include a Phase 1 trial for CT-1119 and a development candidate for fibrosis, with strong industry partnerships supporting progress.
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
PHILADELPHIA , Feb. 19, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky...
Carisma Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025
The conference detailed advances in CAR-macrophage therapies for oncology, fibrosis, and autoimmune diseases, highlighting a shift to in vivo reprogramming and key partnerships. Major milestones include upcoming clinical trials for CT2401 and CT1119, and ongoing collaboration with Moderna on multiple targets.
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
PHILADELPHIA , Feb. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, Presi...
Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline
Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies Development of CT-0525 to be discontinued; workforce reduced b...
Carisma Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference
The company is advancing engineered macrophage therapies for oncology and fibrosis, with a lead HER2-targeted CAR monocyte program in dose escalation and data expected in Q1. Strategic partnerships, notably with Moderna, are expanding the pipeline into in vivo and autoimmune applications.
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
PHILADELPHIA , Nov. 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn...
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024
New preclinical results support the anti-fibrotic potential of engineered macrophages in multiple fibrosis models Engineered TIM4-expressing macrophages correct defective efferocytosis in MASH, demons...
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) PHILADELPHIA , Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeu...
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025 Nomination of a development candidate for liver fibrosis program expected in the first ...
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024
Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors PHILADELPHIA , Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ...
Carisma Therapeutics Announces Changes to its Board of Directors
Appointment of Sohanya Cheng Resignation of Michael Torok PHILADELPHIA , Oct. 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharma...
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024
PHILADELPHIA , Oct. 4, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inno...
Carisma Therapeutics Transcript: Chardan's 8th Annual Genetic Medicines Conference
The company is advancing engineered macrophage therapies across oncology, autoimmune, and fibrosis, with a lead HER2-targeted program in phase I and a major in vivo collaboration with Moderna. Key data readouts and development milestones are expected by year-end and into next year.
Carisma Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024
Four main therapeutic areas are advancing, with lead oncology and fibrosis programs nearing key milestones. Engineered macrophages and monocytes show promise in tumor targeting and fibrosis, supported by a strategic Moderna partnership.
Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
Building on successful pre-clinical in vivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases Moderna nominated two autoimmune disease targets under the collabor...
Carisma Therapeutics to Present at Upcoming Conferences
PHILADELPHIA , Sept. 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn...
Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Initial data for CT-0525, lead product candidate for anti-HER2 program, expected by year-end 2024 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025...
Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024
PHILADELPHIA , Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inno...
Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board
Company appoints renowned key opinion leaders in liver fibrosis, Scott Friedman, MD, and Ira Tabas, MD, PhD PHILADELPHIA , Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Cari...
Carisma Therapeutics Transcript: Stifel 2024 Cell Therapy Forum
The discussion highlighted advances in engineered macrophage therapies, with CT-0525 showing improved tumor infiltration and persistence over earlier candidates. The Moderna partnership is advancing in vivo CAR-M for liver cancer, and preclinical data in fibrosis are promising.
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinoma Nomination triggers a $2 million milestone payment to Carisma PHILADELPHIA , June 27, 202...
Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors
Fast Track designation highlights potential for CT-0525 to address unmet need for patients with solid tumors Initial Phase 1 data expected by year-end 2024 PHILADELPHIA , June 25, 2024 /PRNewswire/ --...